ClinicalExpansion Aethlon is actively expanding its Hemopurifier oncology cohort, signaling ongoing clinical development and potential near-term expansion opportunities with academic centers, contract research organizations, and oncology-focused hospitals seeking innovative immunotherapeutic devices.

FDAMomentum With FDA Breakthrough Device designations for cancer and life-threatening viral infections, there is a compelling pathway for payer discussions, clinician adoption, and faster access programs that sales teams can leverage when engaging hospitals and specialty clinics.

StrategicAlliances The company has engaged Maxim Group as a financial advisor and pursued investor-focused events, presenting opportunities to collaborate with biotech and financial partners for co-development, licensing, or strategic sales channels in oncology and infectious disease workflows.

LongCOVIDCollab Its collaboration with UCSF on Long COVID plasma analyses indicates a potential for expansion into biomarker-driven patient selection and EV-targeting therapies, suggesting cross-selling opportunities with infectious disease and chronic illness programs.

FinancialFit With multi-year revenue in the mid tens of millions and ongoing fundraising activity, there is budgetable demand for early-access programs, site pilots, and value-based demonstrations to convert academic and KOL-led trials into broader institutional adoption.